T. Burke

发表

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan

T. Kijima, H. Kagamu, T. Kamitani, 2022, Cancers.

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

V. Velcheti, M. Pietanza, Xiaohan Hu, 2022, Cancers.

Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective

G. Lopes, R. Insinga, T. Burke, 2021, PharmacoEconomics - Open.

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

L. Crinò, A. Delmonte, G. Bronte, 2022, Cancers.

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

K. Isobe, T. Kamitani, H. Nokihara, 2022, JTO clinical and research reports.

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices

V. Velcheti, Xiaohan Hu, Stephen V. Liu, 2022, Frontiers in Oncology.

Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.

J. Cooper, K. Greven, K. Winter, 2006, Gynecologic oncology.

Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.

B. Halmos, A. Frederickson, B. Piperdi, 2022, Immunotherapy.

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.

B. Halmos, A. Frederickson, B. Piperdi, 2021, Lung cancer.

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

V. Velcheti, M. Pietanza, Xiaohan Hu, 2022, Frontiers in Oncology.

High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

J. Wharton, D. Gershenson, S. Giralt, 2000, Bone Marrow Transplantation.

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices

V. Velcheti, B. Piperdi, Xiaohan Hu, 2021, Scientific Reports.

108P Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC

B. Piperdi, T. Burke, S. Liu, 2021 .

Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

J. Blay, I. Judson, L. Jönsson, 2016, European journal of cancer care.

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

J. Blay, J. Verweij, I. Judson, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.

J. Cooper, K. Greven, K. Winter, 2004, International journal of radiation oncology, biology, physics.

Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.

G. Chodick, V. Shalev, N. Siegelmann-Danieli, 2021, Immunotherapy.

Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019

T. Kamitani, H. Nokihara, K. Aoe, 2023, Current therapeutic research, clinical and experimental.

Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.

V. Velcheti, M. Pietanza, B. Piperdi, 2019, Immunotherapy.